{"id":"NCT00432042","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035)","officialTitle":"An Open, Randomised, Comparative, Multicentre Study of the Immunogenicity and Safety of Concomitant Versus Separate Administration of a Combined Measles, Mumps, Rubella and Varicella Live Vaccine (ProQuad®) and a Booster Dose of Infanrix® Hexa in Healthy Children 12 to 23 Months of Age","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-01-12","primaryCompletion":"2008-03-27","completion":"2008-03-27","firstPosted":"2007-02-06","resultsPosted":"2018-03-19","lastUpdate":"2018-03-19"},"enrollment":955,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Varicella","Measles","Mumps","Rubella","Diphtheria","Tetanus","Pertussis","Poliomyelitis","Hepatitis B","Haemophilus Infections"],"interventions":[{"type":"BIOLOGICAL","name":"ProQuad®","otherNames":[]},{"type":"BIOLOGICAL","name":"Infanrix® hexa","otherNames":[]}],"arms":[{"label":"ProQuad® + Infanrix® hexa","type":"EXPERIMENTAL"},{"label":"ProQuad®","type":"ACTIVE_COMPARATOR"},{"label":"Infanrix® hexa","type":"ACTIVE_COMPARATOR"}],"summary":"Primary Objective:\n\n* To demonstrate that ProQuad® can be administered concomitantly with a booster dose of Infanrix® hexa to healthy children 12 to 23 months of age without impairing either the antibody response rates to measles, mumps, rubella, varicella, hepatitis B and Haemophilus influenzae type b; or to the 3 pertussis antibody titres measured at 42 days following vaccination.\n\nSecondary Objectives:\n\n* To describe the antibody titres and the antibody response rates to measles, mumps, rubella, varicella, diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b as measured at 42 days following vaccination by an Infanrix® hexa primary series schedule and all data are pooled.\n* To evaluate the safety profile of ProQuad® when administered concomitantly with a booster dose of Infanrix® hexa by an Infanrix® hexa primary series schedule and all data are pooled.","primaryOutcome":{"measure":"Percentage of Participants Meeting Antibody Response Rate Criteria to Measles, Mumps, Rubella, and Varicella","timeFrame":"Day 42","effectByArm":[{"arm":"Arm 1: ProQuad® + Infanrix® Hexa","deltaMin":97.4,"sd":null},{"arm":"Arm 2: ProQuad®","deltaMin":96.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"12 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":7,"exclusionCount":16},"locations":{"siteCount":50,"countries":["Germany","Italy"]},"refs":{"pmids":["25765966"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":474},"commonTop":["Injection site erythema","Pyrexia","Injection site pain","Injection site swelling","Nasopharyngitis"]}}